Investing.com -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock plummeted 33% after the company announced its Phase 3 Orbit study for UX143 (setrusumab) in osteogenesis imperfecta patients will ...

Concurrent with the rapidly evolving digital landscape, enterprise data management is poised for transformative change in the coming years. At the same time, organizations driven by exponential data ...

Data analysis from a large-scale retrospective study assessing the clinical advantages of the FIZE kUO system in intensive ...

Second quarterly Car Rental Market Monitor reveals bright spots in EV demand in North America and growing payment method adoption in Europe DUBLIN, July ...